First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.

Cancers (Basel) · 2020 · PMC7352358 · PMID 32517329

Europe PMC DOI

hedged sentence

0.1420

closest p · 2.8× alpha

0.1420

boldest claim

The sentences

showed a trendp = 0.142not close (p > 0.1)

CEUS to absolute dose applied (per cycle 1; Supplementary Tables S2 and S4 ) showed a trend (correlation coefficient r = 0.498, p = 0.142), and DCE-MRI VVF measurements showed a significant correlation with absolute dose applied per cycle 1 (r = 0.556, p = 0.038) but not with dose level per m 2 , whereas k-trans measurements only showed trends.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.